KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Biotechnology

Healthcare
$27.00 +0.00%

+$0.00 today

Market cap
$1.44B
Beta
-0.11
P/E (TTM)
-9.9
EPS (TTM)
-$2.74
52W Low $9.83High $27.00

Volume 4.26M

Average 3.47M

KALV Net Income

Bottom-line profit, the starting point for calculating cash from operations.

KalVista Pharmaceuticals, Inc.NASDAQ: KALV

Net Income · Q4 FY2026 · quarter ended Dec 2025

Net income of -$23.49M in Q4 FY2026

Q4 FY2026 net income was -$23.49M. Trailing-twelve-month net income was -$138.44M.

Context

  • Net income amounted to 223.2% of revenue in FY2026.
  • Net income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of -$57.66M (-64.9%) for the fiscal year ending Dec 2026.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-$23.49M— QoQ
Last fiscal yearDec 2025
-$164.29M— YoY
LTMDec 2025
-$138.44M— YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year—-64.9%—
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2026
(164.29M) USD
Year-over-year change
+10.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How KALV compares with its peers on the latest reported figures

  • KALV's LTM Dec 2025 net income of $138.44M is the 8th largest of the 10 companies compared; the peer median is $160.9M.
  • Net income amounts to 119.4% of revenue for KALV, versus a peer median of 292.9%.
KALV Competitors Peer median
Net Income for KALV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$364.23M +879.7%—121.5%
BCYCBicycle Therapeutics plcLTM Mar 2026$218.8M +7.2%+24.8%344.6%
VSTMVerastem, Inc.LTM Mar 2026$193.96M +30.3%+41.6%391.2%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$185.15M +43.6%+15.7%—
GOSSGossamer Bio, Inc.LTM Mar 2026$180.4M +252.1%-9.4%324.8%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$160.9M -8.8%+9.2%182.3%
PRTAProthena Corporation plcLTM Mar 2026$151.18M +37.1%+27.8%260.9%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$138.44M ——119.4%
ADCTADC Therapeutics S.A.LTM Mar 2026$136.99M -8.6%-3.2%173.0%
OMEROmeros CorporationLTM Mar 2026$81.36M +148.9%-73.6%822.4%
Peer median (excluding KALV) $160.9M+37.1%+12.5%292.9%

Competitors are the stored peer set for KALV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
FY2026
Dec 2025
Net Income(82.34M)(92.91M)(126.64M)(183.44M)(164.29M)
Depreciation & Amortization743K718K816K941K1.45M
Deferred Income Tax00000
Stock-Based Compensation09.92M21.92M12.29M0
Change in Working Capital(12.32M)7.41M15.17M15.04M954K
Accounts Receivables(5.2M)(2.32M)8.18M(3.62M)(7.4M)
Inventory0000(3.43M)
Accounts Payables1.69M1.11M4.32M(4.97M)4.19M
Other Working Capital(8.81M)8.62M2.67M23.63M7.59M
Other Non-Cash Items15.78M(407K)(485K)2.27M80.26M
Operating Cash Flow(78.13M)(75.26M)(89.23M)(152.91M)(81.62M)
Capital Expenditures(931K)(1.2M)(443K)(434K)(1.71M)
Acquisitions (Net)00000
Purchases of Investments(136.92M)(98.25M)(189.23M)(30.57M)(84.78M)
Sales of Investments195.71M140.86M104.96M122.52M105.36M
Other Investing Activities00(401K)00
Investing Cash Flow57.86M41.42M(84.72M)91.02M18.68M
Debt Repayment00098.04M160.72M
Common Stock Issued1.58M56.58M96.95M61.69M1.92M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities01.53M53.77M00
Financing Cash Flow1.58M58.12M150.71M159.73M162.64M
Effect of Forex Changes(1.17M)1.24M(1.21M)1.98M(1.98M)
Net Change in Cash(19.86M)25.51M(24.45M)99.83M97.73M
Free Cash Flow(79.07M)(76.46M)(89.67M)(153.34M)(83.33M)

KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Intrinsic Alpha fair value

Locked

Current Price

$27.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.